The National Institutes of Health has awarded Children’s Hospital Los Angeles $1.7 million to research the brains of premature babies.
The U.S. Food and Drug Administration has approved a cancer therapy developed by Kite Pharma that involves rejiggering a patient’s immune cells to kill cancer.
A quarter of patients admitted to Los Angeles County hospitals are readmitted within 30 days, the highest rate in the state for any county with more than one hospital, according to a recent study.
An East Hollywood nursing home that has been the subject of a flood of complaints for patient abuse and neglect will close this week, with nearly 130 workers to lose their jobs.
Eos Biosciences, a Los Angeles nanomedicines company affiliated with Cedars-Sinai Medical Center, has obtained a patent for a drug delivery platform aimed toward breast cancer.
Two leading Los Angeles medical institutes have developed a liquid biopsy for a cancer of the retina that can blind or kill children younger than 5 years old, researchers announced Monday.
Brentwood-based CytRx Corp. will team up with Patrick Soon-Shiong’s NantCell Inc. of Culver City to test a late-stage cancer drug, CytRx announced Thursday. The company also asked investors Tuesday to approve a one-for-six reverse stock split to continue the company’s listing on the Nasdaq exchange, according to Securities and Exchange Commission filings.
Molina Healthcare Inc. named Joseph M. Zubretsky chief executive Tuesday after a summer that included a layoff announcement and c-suite shakeup.
Children’s Hospital Los Angeles has received a nearly $9 million federal grant to research a new treatment for infants born with severe combined immunodeficiency, commonly known as “bubble boy” syndrome.
ImaginAb Inc., an Inglewood immune-oncology imaging company, has teamed up with a San Francisco cancer institute to launch human clinical trials after receiving $8 million in new funding.
Researchers at City of Hope National Medical Center have won a $13 million grant to fund a clinical trial employing CAR-T cell immunotherapy to kill brain cancer.
Ritter Pharmaceuticals Inc., a Century City biotech company that develops therapies for gastrointestinal diseases, raised $23 million to fund a Phase 3 clinical trial for its lactose intolerance treatment.
Petnet Inc., a privately held Los Angeles company that sells automatic pet feeders for cats and dogs, has received a $3.75 million cash infusion, according to an SEC filing.
HEALTH CARE: Approvals, big deal boost sector’s local profile.
L.A.’s biotech sector shows signs of life with drug approvals and an $11.9 billion deal for Kite.
A congenital heart disease center run by UCLA has just become the first nationally accredited center of its kind in Los Angeles, and the 11th in the U.S.